175 related articles for article (PubMed ID: 30562868)
1. [γδ T cell-based cancer immunotherapy].
Matsushita H; Kakimi K
Nihon Rinsho; 2017 Feb; 75(2):301-305. PubMed ID: 30562868
[TBL] [Abstract][Full Text] [Related]
2. Harnessing γδ T cells in anticancer immunotherapy.
Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
[TBL] [Abstract][Full Text] [Related]
4. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
6. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of γδT cell-based tumor immunotherapy: a meta-analysis.
Buccheri S; Guggino G; Caccamo N; Li Donni P; Dieli F
J Biol Regul Homeost Agents; 2014; 28(1):81-90. PubMed ID: 24750794
[TBL] [Abstract][Full Text] [Related]
8. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
10. In vitro expansion of Vγ9Vδ2 T cells for immunotherapy.
Peters C; Kouakanou L; Oberg HH; Wesch D; Kabelitz D
Methods Enzymol; 2020; 631():223-237. PubMed ID: 31948549
[TBL] [Abstract][Full Text] [Related]
11. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
[TBL] [Abstract][Full Text] [Related]
12. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
Viey E; Laplace C; Escudier B
Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
[TBL] [Abstract][Full Text] [Related]
13. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
15. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
17. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
18. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
19. Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.
Marquez-Medina D; Salla-Fortuny J; Salud-Salvia A
Clin Transl Oncol; 2012 Dec; 14(12):891-5. PubMed ID: 23054752
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
